Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.00
$0.05
N/A-2.8212,887 shs2,201 shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.77
-0.8%
$4.10
$3.51
$7.63
$1.15B0.962.44 million shs1.82 million shs
OptiNose, Inc. stock logo
OPTN
OptiNose
$9.60
$9.57
$4.82
$19.50
$97.22M-0.8863,556 shsN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$1.73
$1.38
$3.79
$117.93M1.08126,298 shs141,800 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-90.00%-99.50%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
MannKind Corporation stock logo
MNKD
MannKind
-0.79%+4.58%-2.84%-19.10%-31.83%
OptiNose, Inc. stock logo
OPTN
OptiNose
0.00%0.00%0.00%+5.84%-41.82%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
2.4185 of 5 stars
3.60.00.00.01.61.71.9
OptiNose, Inc. stock logo
OPTN
OptiNose
0.6544 of 5 stars
1.00.00.04.20.61.70.6
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00
N/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33174.09% Upside
OptiNose, Inc. stock logo
OPTN
OptiNose
2.00
Hold$9.00-6.25% Downside
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest KIN, OPTN, REPH, MNKD, and CALA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
OptiNose, Inc. stock logo
OPTN
OptiNose
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$9.00 ➝ $9.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
MannKind Corporation stock logo
MNKD
MannKind
$285.50M4.01$0.14 per share27.38($0.29) per share-13.00
OptiNose, Inc. stock logo
OPTN
OptiNose
$81.86M1.19N/AN/A($11.56) per share-0.83
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
$75.36M0.00N/AN/A$0.90 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1037.7016.39N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
OptiNose, Inc. stock logo
OPTN
OptiNose
-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%8/6/2025 (Estimated)
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
-$11.37M-$0.31N/AN/AN/A-15.15%-56.66%-11.14%N/A

Latest KIN, OPTN, REPH, MNKD, and CALA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04N/AN/AN/A$77.82 millionN/A
5/13/2025Q1 2025
OptiNose, Inc. stock logo
OPTN
OptiNose
-$0.74-$1.01-$0.27-$1.92$17.70 million$18.51 million
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
OptiNose, Inc. stock logo
OPTN
OptiNose
N/AN/AN/AN/AN/A
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
OptiNose, Inc. stock logo
OPTN
OptiNose
N/A
0.79
0.72
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
2.27
3.24
2.74

Institutional Ownership

CompanyInstitutional Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
66.89%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
OptiNose, Inc. stock logo
OPTN
OptiNose
85.60%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
62.34%

Insider Ownership

CompanyInsider Ownership
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
6.60%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
13.69%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
OptiNose, Inc. stock logo
OPTN
OptiNose
2.30%
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
14.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million295.73 millionOptionable
OptiNose, Inc. stock logo
OPTN
OptiNose
19010.13 million9.83 millionNot Optionable
Recro Pharma, Inc. stock logo
REPH
Recro Pharma
18556.42 million48.41 millionOptionable

Recent News About These Companies

Pharma’s climate change vulnerability and opportunity
Fuji Pharma Co. Ltd.
Here's what Wall Street expects from Recro Pharma's earnings report
Mankind Pharma share price
What Wall Street expects from Recro Pharma's earnings
Mankind Pharma Ltd (MNKI)
Eversana and Amazon plan generative AI push in pharma
Aurobindo Pharma Ltd.
Sun Pharma reports "information security incident"; isolates impacted IT assets
Societal CDMO Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

$0.0001 0.00 (0.00%)
As of 07/11/2025 11:51 AM Eastern

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Kindred Biosciences stock logo

Kindred Biosciences NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.77 -0.03 (-0.79%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.78 +0.01 (+0.16%)
As of 07/11/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

OptiNose stock logo

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)
As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Recro Pharma stock logo

Recro Pharma NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.